Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. Among authors: yokoi t. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer.
Yokoi T, Torii Y, Katashiba Y, Sugimoto H, Tanijiri T, Ogata M, Inagaki N, Kibata K, Hayashi M, Niki M, Shimizu T, Miyara T, Kurata T, Nomura S. Yokoi T, et al. Oncol Lett. 2014 Dec;8(6):2453-2457. doi: 10.3892/ol.2014.2552. Epub 2014 Sep 19. Oncol Lett. 2014. PMID: 25364406 Free PMC article.
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC. Planchard D, et al. Among authors: yokoi t. Clin Lung Cancer. 2016 May;17(3):232-236.e1. doi: 10.1016/j.cllc.2016.03.003. Epub 2016 Mar 17. Clin Lung Cancer. 2016. PMID: 27265743 Free article. Clinical Trial.
Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation.
Kurata T, Nakaya A, Yokoi T, Niki M, Kibata K, Takeyasu Y, Torii Y, Katashiba Y, Ogata M, Miyara T, Nomura S. Kurata T, et al. Among authors: yokoi t. Genes Cancer. 2017 May;8(5-6):559-565. doi: 10.18632/genesandcancer.145. Genes Cancer. 2017. PMID: 28740574 Free PMC article.
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ. Hui R, et al. Among authors: yokoi t. Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7. Lancet Oncol. 2019. PMID: 31601496 Clinical Trial.
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Tamiya A, Iwasawa S, Hata A, Uchida J, Fukuda Y, Hara S, Kanazu M, Hirano K, Kokubo M, Yamamoto N. Sugimoto T, et al. Among authors: yokoi t. Invest New Drugs. 2021 Jun;39(3):853-859. doi: 10.1007/s10637-020-01060-8. Epub 2021 Jan 6. Invest New Drugs. 2021. PMID: 33405089 Clinical Trial.
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N. Ito K, et al. Among authors: yokoi t. Eur J Cancer. 2021 Mar;145:183-193. doi: 10.1016/j.ejca.2020.12.026. Epub 2021 Jan 22. Eur J Cancer. 2021. PMID: 33486442
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S, Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Fujimoto D, et al. Among authors: yokoi t. Eur J Cancer. 2021 Jun;150:63-72. doi: 10.1016/j.ejca.2021.03.016. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892408
1,279 results